The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
geranylgeraniol inhibits the reaction [Fluvastatin results in decreased expression of F3 protein]; geranylgeraniol inhibits the reaction [Simvastatin results in decreased expression of F3]
[geranylgeraniol co-treated with geranyl pyrophosphate] results in decreased expression of HMGCR protein; [MVK gene mutant form results in increased activity of HMGCR protein] which results in increased susceptibility to geranylgeraniol; MVK gene mutant form promotes the reaction [geranylgeraniol results in decreased activity of HMGCR protein]
geranylgeraniol inhibits the reaction [[MVK gene mutant form results in increased susceptibility to Lipopolysaccharides] which results in increased expression of IL1B protein] geranylgeraniol inhibits the reaction [[Alendronate co-treated with Lipopolysaccharides] results in increased expression of IL1B protein]
geranylgeraniol inhibits the reaction [Atorvastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein]]; geranylgeraniol inhibits the reaction [Pravastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein]]
geranylgeraniol inhibits the reaction [Atorvastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein]]; geranylgeraniol inhibits the reaction [Pravastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein]]
[MVK gene mutant form results in increased activity of HMGCR protein] which results in increased susceptibility to geranylgeraniol; geranylgeraniol inhibits the reaction [[MVK gene mutant form results in increased susceptibility to Lipopolysaccharides] which results in increased expression of IL1B protein]; geranylgeraniol inhibits the reaction [MVK gene mutant form results in increased susceptibility to Lipopolysaccharides]; MVK gene mutant form promotes the reaction [geranylgeraniol results in decreased activity of HMGCR protein]
geranylgeraniol inhibits the reaction [Simvastatin results in increased expression of PLAT mRNA]; geranylgeraniol inhibits the reaction [Simvastatin results in increased expression of PLAT]
geranylgeraniol inhibits the reaction [cerivastatin promotes the reaction [Bezafibrate results in increased activity of [PPARA protein binds to RXRA protein]]]
geranylgeraniol inhibits the reaction [Lovastatin affects the localization of RAC1 protein] Geranylgeraniol inhibits the reaction [Ropivacaine decreases activity of RAC1 protein in esophageal carcinoma cells]
[geranylgeraniol co-treated with geranyl pyrophosphate] results in decreased expression of RAP1A protein modified form; geranylgeraniol inhibits the reaction [zoledronic acid results in decreased geranoylation of RAP1A protein]
geranylgeraniol analog inhibits the reaction [EGF protein results in increased phosphorylation of RHOA protein]; geranylgeraniol analog inhibits the reaction [lysophosphatidic acid results in increased activity of RHOA protein]; geranylgeraniol inhibits the reaction [Lovastatin affects the localization of RHOA protein]; geranylgeraniol inhibits the reaction [Simvastatin results in decreased geranoylation of and affects the localization of RHOA protein]; geranylgeraniol inhibits the reaction [Zoledronic Acid results in decreased expression of and affects the localization of RHOA protein] geranylgeraniol inhibits the reaction [Lovastatin affects the localization of RHOA protein]; geranylgeraniol inhibits the reaction [Simvastatin inhibits the reaction [Phenylephrine results in increased activity of RHOA protein]]
geranylgeraniol inhibits the reaction [cerivastatin promotes the reaction [Bezafibrate results in increased activity of [PPARA protein binds to RXRA protein]]]
browse the term
